Related Experiment Video
Updated: Jul 13, 2026
09:41
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
Thrombomodulin overexpression to limit neointima formation.
J M Waugh1, J Li-Hawkins, E Yuksel
1Department of Cell Biology, Baylor College of Medicine, Houston, Tex.
Circulation
|July 19, 2000
Summary
High-level thrombomodulin overexpression effectively limits neointima formation after arterial injury. This adenoviral vector (Adv/RSV-THM) reduces inflammation and thrombus, preserving vessel matrix for artery repair.
Area of Science:
- Vascular Biology
- Gene Therapy
- Cardiovascular Research
Background:
- Neointima formation is a key factor in post-injury vascular remodeling.
- Thrombomodulin plays a crucial role in regulating coagulation and inflammation.
- Previous studies suggest thrombomodulin's potential in limiting vascular hyperplasia.
Purpose of the Study:
- To confirm if high-level thrombomodulin overexpression can prevent neointima formation after mechanical injury.
- To evaluate the efficacy of an adenoviral vector delivering thrombomodulin (Adv/RSV-THM) in a rabbit model.
Main Methods:
- An adenoviral construct (Adv/RSV-THM) was developed and tested in vitro and in vivo.
- New Zealand White rabbits underwent mechanical overdilation injury to femoral arteries.
- Arteries were treated with buffer, viral control, or Adv/RSV-THM and analyzed after 28 days for intima-to-media ratios.
Main Results:
- Adv/RSV-THM significantly reduced neointima formation (I/M ratio 0.47) compared to controls (0.76-0.77).
- Early analysis showed decreased local inflammation, thrombus formation, and preserved matrix in the Adv/RSV-THM group.
- The construct demonstrated functional characterization in vitro and in vivo.
Conclusions:
- Adenoviral-mediated thrombomodulin overexpression is sufficient to limit neointima formation.
- Adv/RSV-THM offers a viable strategy for creating neointima-resistant arteries.
- This approach minimizes inflammatory damage associated with adenoviral applications.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.